Omios Biologics articulated the vision behind its Biologics and ODE platform.
Published
Signal category
Strategy & Corporate Development
Quote
“Aldo Pourchet, for articulating the vision behind Omios Biologics and ODE so clearly!”
— Bruno Larida|Omios Biologics team
Company
Omios Biologics
Hacking virus evolution to engineer tomorrow's cures.
- Industry
- Biotechnology Research
- Location
- Stony Brook, US
- Company size
- 6 employees
Nature spent millennia engineering viruses to manipulate human biology. We decoded it. Omios Biologics is a biotech company revolutionizing precision drug discovery through the Omios Discovery Engine (ODE), our computational platform that decodes viral-host interactions to build high-potency, high-selectivity therapeutics. By analyzing how over 270 human viruses exploit cellular pathways, ODE eliminates the guesswork of traditional drug discovery, pinpointing validated targets before a molecule is ever synthesized. Originally focused on developing biomarker-driven oncolytic viruses for hard-to-treat solid tumors (including breast, lung, pancreatic, and kidney cancers), Omios is now leveraging its platform across immunology, inflammation, metabolic, and neurodegenerative diseases. Powered by a team with deep expertise in virology, computational biology, and clinical drug development, Omios is replacing trial-and-error with predictive engineering to deliver the next generation of targeted cures.
Founded 2023